Full Press Release Details
CEO Dr. Michael West to Present at World Stem Cell Summit 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--November 29, 2012--BioTime, Inc. (NYSE
MKT: BTX), a biotechnology company that develops and markets products in
the field of regenerative medicine, today announced that Chief Executive
Officer Michael D. West, Ph.D. will present at the World Stem Cell
Summit 2012 in West Palm Beach, Florida on Tuesday, December 4, 2012.
Dr. West will be presenting in the session on "Developing Combination
Products: Cells, Genes, and Devices" at 1:30 pm EST which will include
an update on product development, including Renevia , PanC-Dx ,
and OpRegen . The presentation will be made
available on BioTime's website at www.biotimeinc.com.
World Stem Cell Summit 2012 will be the 8th annual event produced by the
Genetics Policy Institute (GPI), a non-profit organization. Planned by
and for the stem cell and regenerative medicine community, the goal of
the Summit is to accelerate the discovery and development of lifesaving
cures and therapies. This year, panels will address advancing treatments
for specific diseases and conditions including: cancer, diabetes,
HIV/AIDS, cardiovascular disease, spinal cord injury, paralysis,
multiple sclerosis, ALS, Parkinson's, eye diseases and others.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem
cell lines, HyStem hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia (formerly
known as HyStem -Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc. markets GeneCards , the
leading human gene database, and is developing an integrated database
suite to complement GeneCards that will also
include the LifeMap database of embryonic development, stem cell
research and regenerative medicine, and MalaCards, the human
disease database. LifeMap will also market BioTime research products.
BioTime's lead product, Hextend , is a blood
plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under
exclusive licensing agreements. Additional information about BioTime can
be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts
Chief Financial Officer